ADAM17 Antibody

What is ADAM17 and why is it important in research?

ADAM17 is a membrane-bound metalloprotease that plays a significant role in cell signaling through its shedding activity. In humans, the canonical ADAM17 protein consists of 824 amino acid residues with a molecular weight of approximately 93 kDa . It is ubiquitously expressed across many tissue types and is involved in critical biological processes including B cell differentiation and cell adhesion . ADAM17 has gained significant research attention due to its alpha-secretase activity, which can prevent the production of neurotoxic amyloid peptides implicated in neurodegenerative diseases . Additionally, ADAM17 dysfunction has been associated with inflammatory skin and bowel diseases, making it an important target for therapeutic development .

What are the common applications for ADAM17 antibodies in research?

ADAM17 antibodies are versatile tools employed in numerous research applications:

These applications enable researchers to investigate ADAM17 expression, localization, and function in various experimental contexts .

What are the known isoforms of ADAM17 and how do they affect antibody selection?

Up to two different isoforms of ADAM17 have been reported in humans . When selecting antibodies for ADAM17 detection, researchers should consider which epitopes are present in their isoform of interest. Some antibodies are raised against specific domains (e.g., antibodies targeting Arg215-Asn671 region as mentioned in the R&D Systems antibody ). Checking the exact epitope recognition site is crucial for experiments focusing on specific ADAM17 variants or truncated forms. Additionally, antibodies targeting the cytoplasmic domain may not be suitable for detecting ADAM17Δ-cyto variants used in functional studies .

How should ADAM17 antibodies be validated before experimental use?

Before using ADAM17 antibodies in critical experiments, thorough validation is recommended:

• Specificity testing: Verify antibody specificity using positive controls (tissues/cells known to express ADAM17) and negative controls (ADAM17 knockout models or cells)

• Cross-reactivity assessment: If working with non-human samples, confirm cross-reactivity with the species of interest

• Application-specific optimization: Determine optimal antibody concentration for each application (e.g., 1 μg/mL for Western blot as used in R&D Systems protocol )

• Epitope accessibility verification: For fixed samples, confirm that your fixation method preserves the target epitope (e.g., heat-induced epitope retrieval using basic antigen retrieval reagent as described in immunohistochemistry protocols )

Proper validation ensures reliable and reproducible results across different experimental conditions.

How does ADAM17 activity differ from ADAM10, and how can antibodies help distinguish their functions?

ADAM17 and ADAM10 share several substrates but exhibit distinct activation patterns and substrate preferences. Research has shown that:

• Differential response to stimuli: ADAM17 responds to specific signaling pathways that do not activate ADAM10

• Substrate selectivity: When both enzymes are active (e.g., in BzATP-stimulated cells), ADAM17 shows preferential shedding of certain substrates like CD62L compared to ADAM10

• Processing kinetics: ADAM17-mediated shedding of CD62L is significantly more rapid than ADAM10-mediated processing

To distinguish between ADAM17 and ADAM10 functions, researchers can employ:

• Selective inhibitors (e.g., GI at 1 μM concentration selectively inhibits ADAM10 without affecting ADAM17 activity)

• Specific antibodies targeting unique epitopes of each protein

• Knockout/knockdown models lacking either or both proteases (e.g., Adam17−/− or Adam10/17−/− models)

These approaches enable researchers to dissect the relative contributions of each enzyme to observed biological effects.

What is known about post-translational modifications of ADAM17 and how do they affect antibody recognition?

ADAM17 undergoes several post-translational modifications that can influence its detection by antibodies:

• Glycosylation: ADAM17 contains multiple glycosylation sites that modify its apparent molecular weight and potentially mask epitopes

• Proteolytic processing: The removal of the pro-domain during maturation changes the protein's conformation and epitope accessibility

• Phosphorylation: ADAM17 can be phosphorylated at multiple sites, including T735, which affects its activity and potentially antibody recognition

When selecting antibodies for ADAM17 detection, consider:

• Whether your experiment requires detection of specific post-translationally modified forms

• If site-specific antibodies are needed (e.g., anti-ADAM17 phospho T735 antibodies used in phosphorylation studies)

• Whether the antibody recognizes the mature or pro-form of ADAM17

These considerations are particularly important when studying ADAM17 activation mechanisms or when performing quantitative analyses of active versus inactive forms.

How can ADAM17 antibodies be used to investigate its role in pathological conditions?

ADAM17 antibodies have been instrumental in elucidating the role of this enzyme in various disease states:

• Neurodegenerative diseases: Immunohistochemical staining with ADAM17 antibodies has helped investigate its alpha-secretase activity in relation to amyloid beta plaque formation in Alzheimer's disease models

• Inflammatory conditions: ADAM17 expression analysis using specific antibodies has revealed its involvement in inflammatory skin and bowel diseases

• Cancer research: Immunodetection of ADAM17 in exosomes derived from melanoma cells has provided insights into cancer progression mechanisms

Research findings demonstrate that:

• ADAM17 overexpression in APP/PS1 mice (a model of Alzheimer's disease) improves cognitive function as measured by Novel Object Recognition tests

• Despite improving cognitive outcomes, ADAM17 overexpression did not significantly reduce amyloid-β plaque density in APP/PS1 mice, suggesting complex mechanisms beyond simple plaque reduction

These applications highlight how ADAM17 antibodies can uncover mechanistic insights into disease pathogenesis and potential therapeutic targets.

What experimental considerations are critical when using ADAM17 antibodies in activation studies?

When studying ADAM17 activation mechanisms:

• Rapid and reversible activation: Research has shown that ADAM17 activation is rapid and potentially reversible, requiring careful experimental timing

• Domain requirements: Studies using domain-deletion mutants (e.g., ADAM17Δ-cyto) have demonstrated that the cytoplasmic domain is not required for ADAM17 to respond to physiological stimuli, while catalytic activity depends on the glutamic acid in the catalytic domain (ADAM17E>A mutants lack activity)

• Substrate selection: When measuring ADAM17 activation, selecting appropriate substrates is crucial, as some substrates may be processed by both ADAM17 and ADAM10

Experimental approach recommendations:

• Include appropriate controls (wild-type vs. ADAM17-deficient cells, catalytically inactive mutants)

• Use selective inhibitors to distinguish between ADAM10 and ADAM17 activities

• Consider time-dependent activation dynamics in experimental design

These considerations help ensure robust and interpretable results when investigating ADAM17 activation mechanisms.

What are the optimal sample preparation methods for detecting ADAM17 in different experimental systems?

Sample preparation varies by application and sample type:

For Western Blot analysis:

• Use appropriate lysis buffers containing protease inhibitors

• When analyzing membrane proteins like ADAM17, include detergents (e.g., Triton X-100 or NP-40)

• Process under reducing conditions using Immunoblot Buffer Group 1 for optimal detection

• Expect to visualize ADAM17 at approximately 100 kDa

For Immunohistochemistry:

• For formalin-fixed, paraffin-embedded (FFPE) tissues: Perform heat-induced epitope retrieval using basic antigen retrieval reagents

• Apply ADAM17 antibody at optimized concentration (e.g., 3 μg/mL) overnight at 4°C

• Use appropriate detection systems (e.g., HRP-DAB for bright-field microscopy)

• Include both positive controls (tissues with known ADAM17 expression) and negative controls

For Flow Cytometry:

• Use single-cell suspensions with preserved cell surface proteins

• Block Fc receptors to reduce non-specific binding

• Optimize antibody concentration through titration experiments

• Include appropriate isotype controls

Proper sample preparation ensures optimal sensitivity and specificity for ADAM17 detection across different experimental platforms.

How can researchers effectively compare different ADAM17 antibodies for their specific applications?

When selecting from multiple ADAM17 antibodies:

• Epitope mapping: Compare the epitope recognition sites and determine which antibody best suits your research question

• Cross-reactivity profile: Evaluate species cross-reactivity if working with non-human models

• Application validation: Review published data on antibody performance in your specific application (e.g., Western blot, IHC, flow cytometry)

• User reviews and published literature: Examine user-generated data and peer-reviewed publications using specific antibodies

A systematic comparison approach includes:

By systematically evaluating these parameters, researchers can select the most appropriate ADAM17 antibody for their specific research needs.

What are the recommended protocols for detecting phosphorylated forms of ADAM17?

Detecting phosphorylated ADAM17 requires specialized approaches:

• Antibody selection: Use phospho-specific antibodies that recognize ADAM17 phosphorylated at specific residues (e.g., anti-ADAM17 phospho T735 antibody)

• Phosphatase inhibition: Include phosphatase inhibitors (e.g., sodium orthovanadate, β-glycerophosphate) in all buffers during sample preparation

• Sample handling: Process samples rapidly at 4°C to preserve phosphorylation status

• Validation: Confirm specificity using phosphatase-treated controls

Immunoprecipitation protocol for phosphorylated ADAM17:

• Lyse cells in buffer containing phosphatase and protease inhibitors

• Pre-clear lysates with protein A/G beads

• Incubate cleared lysates with anti-ADAM17 antibody

• Capture immune complexes with protein A/G beads

• Wash extensively to remove non-specific interactions

• Elute and analyze by Western blot using phospho-specific antibodies

This approach allows for enrichment and specific detection of phosphorylated ADAM17 species.

How can researchers design experiments to distinguish between ADAM17 and ADAM10 activities using antibodies?

To differentiate between ADAM17 and ADAM10 activities:

• Selective inhibition: Use GI at 1 μM concentration, which selectively inhibits ADAM10 without affecting ADAM17

• Genetic approaches: Utilize Adam17−/−, Adam10−/−, or Adam10/17−/− double knockout cell models for definitive activity attribution

• Substrate selection: Choose substrates with preferential cleavage by one enzyme (e.g., CD62L for ADAM17)

• Kinetic analysis: Measure substrate shedding at multiple early time points to capture the rapid action of ADAM17 compared to ADAM10

Experimental workflow example:

• Prepare wild-type, Adam17−/−, and Adam10−/− cells

• Stimulate cells with activators (e.g., BzATP, ionomycin)

• Measure substrate shedding at multiple timepoints (0, 5, 15, 30 min)

• Use selective inhibitors in parallel experiments

• Confirm results with rescue experiments using wild-type or mutant ADAM17 constructs (e.g., ADAM17E>A, ADAM17Δ-cyto)

These approaches provide complementary evidence to definitively attribute observed shedding activities to specific enzymes.

What are common challenges in ADAM17 antibody-based detection and how can they be overcome?

Researchers frequently encounter several challenges when working with ADAM17 antibodies:

• Non-specific binding: ADAM17 antibodies may cross-react with related ADAM family members

  • Solution: Use antibodies validated against knockout controls and perform pre-absorption tests

• Low signal intensity: Membrane proteins like ADAM17 can be difficult to extract and detect

  • Solution: Optimize extraction buffers with appropriate detergents and increase protein loading; consider using signal enhancement systems for detection

• Variable glycosylation: Post-translational modifications affect antibody recognition

  • Solution: Consider enzymatic deglycosylation (PNGase F treatment) before analysis

• Isoform-specific detection: Distinguishing between ADAM17 isoforms can be challenging

  • Solution: Select antibodies with epitopes specific to your isoform of interest

• Fixation artifacts in immunohistochemistry: Some fixatives may mask ADAM17 epitopes

  • Solution: Optimize antigen retrieval methods; test multiple antibodies targeting different epitopes

Addressing these challenges systematically improves the reliability and reproducibility of ADAM17 detection across experimental systems.

How should researchers interpret contradictory results when using different ADAM17 antibodies?

When faced with contradictory results from different ADAM17 antibodies:

• Epitope mapping: Different antibodies recognize distinct epitopes that may be differentially accessible in various experimental conditions

  • Action: Map the exact epitopes recognized by each antibody and consider accessibility in your experimental system

• Expression context: ADAM17 activity and conformation may vary across cell types and conditions

  • Action: Validate findings across multiple experimental systems and conditions

• Technical variables: Buffer compositions, incubation times, and detection methods influence results

  • Action: Standardize protocols and test multiple antibodies under identical conditions

• Antibody validation status: Not all commercially available antibodies undergo rigorous validation

  • Action: Prioritize results from antibodies with published validation data in systems similar to yours

When possible, use complementary approaches (e.g., genetic knockdown/knockout, activity assays) to validate antibody-based findings and resolve contradictions.

What strategies can improve the detection of low-abundance ADAM17 in biological samples?

For detecting low-abundance ADAM17:

• Sample enrichment:

  • Concentrate membrane fractions through ultracentrifugation

  • Perform immunoprecipitation to enrich ADAM17 before analysis

  • Use larger sample volumes for extraction

• Signal amplification:

  • Employ tyramide signal amplification for immunohistochemistry

  • Use high-sensitivity chemiluminescent substrates for Western blot

  • Consider biotin-streptavidin amplification systems

• Instrument optimization:

  • Increase exposure times for Western blots (while monitoring background)

  • Adjust detector sensitivity for flow cytometry

  • Use confocal microscopy with optimal pinhole settings for immunofluorescence

• Antibody optimization:

  • Test multiple antibody concentrations to determine optimal signal-to-noise ratio

  • Consider cocktails of multiple antibodies targeting different ADAM17 epitopes

  • Use high-affinity antibodies with demonstrated sensitivity

These approaches collectively enhance detection sensitivity while maintaining specificity for low-abundance ADAM17 detection.

How might new antibody technologies advance ADAM17 research?

Emerging antibody technologies offer new opportunities for ADAM17 research:

• Single-domain antibodies (nanobodies): Their smaller size enables access to epitopes inaccessible to conventional antibodies, such as active site pockets or cryptic epitopes in ADAM17

• Conformation-specific antibodies: These can distinguish between active and inactive ADAM17 conformations, providing direct readouts of activation status

• Multiplexed detection systems: Simultaneous detection of ADAM17 along with its substrates and regulatory proteins provides contextual information about activity networks

• Intrabodies: Genetically encoded antibody fragments expressed within cells can track ADAM17 trafficking and activation in real-time

• Proximity-based labeling: Antibody-guided enzyme proximity labeling can identify new ADAM17 interaction partners and substrates

These technologies will enable more precise spatial, temporal, and functional analysis of ADAM17 in complex biological systems.

What are promising applications of ADAM17 antibodies in therapeutic development and diagnostics?

ADAM17 antibodies show significant potential in translational applications:

• Therapeutic development:

  • Neutralizing antibodies targeting ADAM17 could modulate its activity in inflammatory diseases

  • Antibody-drug conjugates could deliver therapeutics to cells overexpressing ADAM17

  • Imaging therapeutic response through ADAM17 expression monitoring

• Diagnostic applications:

  • Biomarker development for conditions associated with ADAM17 dysregulation

  • ADAM17 activity assays to monitor disease progression

  • Companion diagnostics for therapies targeting ADAM17-dependent pathways

• Mechanistic insights:

  • Elucidating ADAM17's role in neurodegenerative disease progression

  • Understanding how ADAM17 contributes to inflammatory cascades

  • Exploring ADAM17's dual roles in development and disease

These applications highlight ADAM17's growing importance as both a research target and a clinically relevant molecule.